User:Mr. Ibrahem/Decitabine
 | |
| Clinical data | |
|---|---|
| Trade names | Dacogen |
| Other names | 5-aza-2'-deoxycytidine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608009 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Pyrimidine analog[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | <1% |
| Elimination half-life | 30 minutes |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C8H12N4O4 |
| Molar mass | 228.208 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Decitabine, sold under the brand name Dacogen, is a medication used to treat myelodysplastic syndromes and acute myeloid leukemia (AML).[2][3] In AML it is used for older people who do not qualify for typical induction chemotherapy.[1] It is given by injection into a vein.[2]
Common side effects include fever, low red blood cells, and low platelets.[3] Other side effects may include pneumonia.[3] Use in pregnancy may harm the baby.[2] It is a pyrimidine analog and works by blocking DNA methyltransferase.[1][3]
Decitabine was approved for medical use in the United States in 2006 and Europe in 2012.[2][3] In the United Kingdom 50 mg costs the NHS about £970 as of 2021.[1] In the United States this amount costs about 214 USD.[4]
References[edit]
- ^ a b c d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 954. ISBN 978-0857114105.
- ^ a b c d e "Decitabine Monograph for Professionals". Drugs.com. Archived from the original on 17 August 2019. Retrieved 21 December 2021.
- ^ a b c d e f g "Dacogen". Archived from the original on 18 November 2021. Retrieved 21 December 2021.
- ^ "Decitabine Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 21 December 2021.